Dr Matous on Ongoing Multiple Myeloma Clinical Trials at Colorado Blood Cancer Institute

Jeffrey V. Matous, MD, member physician, Colorado Blood Cancer Institute, clinical professor of medicine, University of Colorado, discusses upcoming and ongoing clinical trials in multiple myeloma being conducted at Colorado Blood Cancer Institute.

Cellular therapies remain a key area of interest in clinical trials for patients with multiple myeloma, Matous begins. Along with traditional CAR T-cell therapies, other cellular therapy approaches under investigation include natural killer cells, he notes. Furthermore, CAR T-cell therapies with novel targets beyond BCMA, such as GPRC5D and dual-targeting CAR T-cell therapies, are being evaluated, Matous says.

Continued investigations of BCMA-directed CAR T-cell therapies and bispecific antibodies are ongoing Colorado Blood Cancer Institute, including the phase 2 MajesTEC-1 trial (NCT04557098), which is evaluating teclistamab-cqyv (Tecvayli) in patients with relapsed/refractory multiple myeloma, Matous continues. The phase 1 TRIMM-3 trial (NCT05338775) is also investigating teclistamab or talquetamab in combination with a PD-1 inhibitor. Additionally, talquetamab is also being explored in various combinations in the phase 1 MonumenTAL-2 trial (NCT05050097). Studies of novel bispecific and trispecific antibodies are also planned, he adds.

One study of note that will soon open at Colorado Blood Cancer Institute is the ongoing phase 1/2 RedirecTT-1 trial (NCT04586426), which is evaluating the combination talquetamab and teclistamab in patients with relapsed/refractory multiple myeloma who have extramedullary disease. This study aims to address an area of major unmet need, Matous concludes.